Prognostic Factors for Survival in Patients With Recurrent Cervical Cancer Previously Treated With Radiotherapy

被引:62
作者
Mabuchi, Seiji [1 ]
Isohashi, Fumiaki [2 ]
Yoshioka, Yasuo [2 ]
Temma, Kumiko [1 ]
Takeda, Takashi [1 ]
Yamamoto, Toshiya [1 ]
Enomoto, Takayuki [1 ]
Morishige, Kenichirou [1 ]
Inoue, Takehiro [2 ]
Kimura, Tadashi [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Suita, Osaka 5650871, Japan
关键词
Prognostic factors; Recurrent cervical cancer; Survival; Radiotherapy; Chemotherapy; GYNECOLOGIC-ONCOLOGY-GROUP; FOLLOW-UP PROCEDURES; PHASE-III TRIAL; UTERINE CERVIX; RADICAL HYSTERECTOMY; CARCINOMA; CISPLATIN; SURVEILLANCE; SURGERY;
D O I
10.1111/IGC.0b013e3181dcadd1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The aim of this study was to identify the prognostic factors and to establish a model for the prediction of life expectancy in patients with recurrent cervical cancer that had previously been treated with radiotherapy. Methods: The records of consecutive women with recurrent cervical cancer after radiotherapy were retrospectively reviewed. Primary disease, follow-up, and recurrence data were collected. Univariate and multivariate analyses of prognostic factors of survival were performed. Results: A total of 162 patients were included in our database. The median survival after recurrence was 15 months. Multivariate analysis revealed that symptom status, the site of relapse, prior chemoradiotherapy, and treatment modality were significant prognostic factors in terms of survival after recurrence. Patient survival was inversely correlated with the number of these prognostic factors. When the patients were divided into 3 prognostic groups, (low risk: patients with no poor prognostic factors; intermediate: patients with one poor prognostic factor; and high-risk: patients with more than 2 poor prognostic factors), the patients in the high-risk group had a significantly shorter survival (median, 10 months) than those with one risk factor (median, 20 months) or no risk factors (median, 36 months). Conclusions: Symptom status, the site of relapse, prior chemoradiotherapy, and treatment modality are significant prognostic factors in patients with recurrent cervical cancer that had previously been treated with radiotherapy. Our prognostic model, composed of 4 clinical variables, may enable physicians to predict survival more accurately.
引用
收藏
页码:834 / 840
页数:7
相关论文
共 22 条
  • [1] Ajiki W, 2004, JPN J CLIN ONCOL, V34, P352, DOI 10.1093/jjco/hyh056
  • [2] [Anonymous], 2022, CA-CANCER J CLIN
  • [3] Carcinoma of the cervix uteri
    Benedet, JL
    Odicino, F
    Maisonneuve, P
    Beller, U
    Creasman, WT
    Heintz, APM
    Ngan, HYS
    Pecorelli, S
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2003, 83 : 41 - 78
  • [4] Posttherapy surveillance of women with cervical cancer: An outcomes analysis
    Bodurka-Bevers, D
    Morris, M
    Eifel, PJ
    Levenback, C
    Bevers, MW
    Lucas, KR
    Wharton, JT
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 78 (02) : 187 - 193
  • [5] Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design
    Brader, KR
    Morris, M
    Levenback, C
    Levy, L
    Lucas, KR
    Gershenson, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1879 - 1884
  • [6] Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer
    Brooks, Rebecca A.
    Rader, Janet S.
    Dehdashti, Farrokh
    Mutch, David G.
    Powell, Matthew A.
    Thaker, Premal H.
    Siegel, Barry A.
    Grigsby, Perry W.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 104 - 109
  • [7] Recurrent cervical cancer: detection and prognosis
    Duyn, A
    Van Eijkeren, M
    Kenter, G
    Zwinderman, K
    Ansink, A
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2002, 81 (04) : 351 - 355
  • [8] Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix
    Eralp, Y
    Saip, P
    Sakar, B
    Kucucuk, S
    Aydiner, A
    Dincer, M
    Aslay, I
    Topuz, E
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (04) : 497 - 504
  • [9] Friedlander M, 2002, ONCOLOGIST, V7, P342
  • [10] The role of routine follow-up after gynecological malignancy
    Kew, FM
    Roberts, AP
    Cruickshank, DJ
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (03) : 413 - 419